The incorporated diagnostic biomarkers in the 2016 WHO classification of gliomas were Isocitrate dehydrogenase (IDH)-1/2 mutations, 1p/19q codeletion, H3 Histone, Family 3A (H3F3A) or HIST1H3B/C K27M (H3-K27M) mutations, and C11orf95–RELA fusions [13]. This evidence concerns the gene RELA and central nervous system cancer.